Edap TMS publishes investor deck on Focal One robotic HIFU focal therapy growth strategy

• Edap TMS outlined a strategy shift toward a pure-play robotic focal therapy focus, centered on its Focal One HIFU platform.
• HIFU revenue shown rising to 52 million by CY26E, from 37 million in CY25; 3-year CAGR cited at 32% with 40% year-over-year growth.
• Presentation highlighted prostate cancer as a key growth driver, citing more than 330,000 new U.S. cases annually.
• Focal therapy market share projected at about 40% over time, positioning HIFU as a fast-growing treatment option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.